Pelvic Inflammatory Disease Clinical Trial
Official title:
The Importance of Anti-anaerobic Therapy for Acute PID
Verified date | July 2018 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a randomized placebo-controlled trial comparing two antibiotic treatment regimens for acute PID. Women with acute PID will be randomized to one of two treatment regimens: 1) a single intramuscular dose of ceftriaxone 250 mg, doxycycline 100 mg orally twice a day for 14 days, along with placebo tablets orally twice a day for 14 days or 2) same doses of ceftriaxone and doxycycline, and metronidazole 500 mg orally twice a day for 14 days. The primary objective is to compare the eradication of anaerobic organisms from the upper genital tract between women who receive standard outpatient antibiotic treatment to those who receive standard outpatient treatment along with a two-week course of metronidazole.
Status | Completed |
Enrollment | 233 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 15 Years to 40 Years |
Eligibility |
Inclusion Criteria: Women must meet all of the following inclusion criteria: 1. Age 15-40 at the time of enrollment (Note: Participants between the ages of 15-17 will require written informed consent from parent/legal guardian. Written assent will also be obtained from the minor) 2. Acute PID, defined by symptoms and signs guided by current CDC guidelines:50 1. Current symptoms of lower abdominal or pelvic pain (present for =30 days) AND 2. Cervical motion tenderness AND/OR uterine tenderness AND/OR adnexal tenderness on pelvic examination 3. Ability to provide written informed consent Exclusion Criteria: Women with any of the following will be ineligible to participate: 1. Pregnant or nursing a baby (Note: a urine pregnancy test will be done at enrollment. Result must be negative to participate in the study.) 2. Uterine procedure (e.g. dilation and curettage, abortion) or miscarriage within the past 6 weeks. 3. Allergy to any of the study medications (cephalosporins, doxycycline, or metronidazole) or Type 1 hypersensitivity allergic reaction to penicillin for those with unknown tolerance to cephalosporins. 4. Systemic or vaginal antibiotic therapy in the preceding 7 days 5. Requires inpatient PID therapy (per the current CDC guidelines)50 6. Inability to obtain an endometrial biopsy at enrollment 7. Known inability to comply with the follow-up visits 8. Prior hysterectomy 9. Menopause (including natural menopause defined as lack of menses for 12 consecutive months [in the absence of pregnancy] and surgical menopause defined as a woman who has had both ovaries removed) 10. Inability to swallow pills 11. Not willing to refrain from alcohol during the two week treatment period (and two additional days following completion of study medication) 12. Other condition present at enrollment that requires additional antibiotic treatment 13. Current use of any of the following medications: - Anticoagulants, coumarin- or indandione-derivative: warfarin - cimetidine (Tagamet) - Disulfiram - Seizure medications including: phenytoin (Dilantin), carbamezapine (Tegretol), barbiturates (i.e. Phenobarbital) - Lithium - Immunosuppressive drugs including: cyclosporine, amprenavir - Antacids, minerals or bismuth subsalicylate (Pepto Bismol) 14. Any condition, in the opinion of the investigator that would interfere with the participant's safety or with study outcomes 15. Participation in any study involving an investigational product in the past 30 days or anticipation of participation in any study using an investigational product in the next 30 days 16. Previous participation in this study 17. Evidence of a tuboovarian abscess |
Country | Name | City | State |
---|---|---|---|
United States | Allegheny County Health Department Sexually Transmitted Diseases Clinic | Pittsburgh | Pennsylvania |
United States | Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania |
United States | UPMC Mercy Hospital | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Harold Wiesenfeld | National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clearance of Anaerobic Organisms From the Endometrium | Clearance of anaerobic microorganisms from the endometrium at the 30 day follow-up visit among women who had anaerobic microorganisms detected in their endometrial tissue sample at enrollment. Clearance is defined as no anaerobic microorganisms detected in the endometrial tissue biopsy sample collected at the 30-day visit. | Enrollment to 30 days | |
Secondary | The Prevalence of M. Genitalium in the Cervix and Endometrium From Women With Acute PID. | The number of women who had M. genitalium detected in cervical and endometrial biopsy cultures by nucleic acid amplification tests at enrollment. | enrollment | |
Secondary | The Eradication of M. Genitalium From the Lower and Upper Genital Tract Following Antibiotic Therapy for Acute PID. | M. genitalium not detected in the cervical and endometrial cultures by nucleic acid amplification testing at the 30 day visit among women who had M. genitalium detected at either anatomical site at the enrollment visit. | Enrollment to 30 days | |
Secondary | Resolution of Clinical Signs and Symptoms of Acute PID - Intention to Treat Analysis | Clinical response to treatment is improvement (reduction) of the McCormack Scale total score from baseline to day 3 follow-up visit. Participants without a 3-day measure were considered treatment failures. | Enrollment to 3 day follow up visit | |
Secondary | Identification of Endometrial Microorganisms Present Obtained From Women With or Without Evidence of Endometritis. | Identification of endometrial microorganisms present obtained from women with or without evidence of endometritis using a combination of culture methods, rRna sequencing and whole genomic sequencing. The aim is to identify the etiology of endometritis. | enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04723069 -
Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases
|
Phase 2 | |
Recruiting |
NCT03391440 -
A Trial to Assess the Efficacy and Safety of Morinidazole in Women With Pelvic Inflammatory Disease
|
Phase 4 | |
Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
Completed |
NCT00115388 -
Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease
|
N/A | |
Not yet recruiting |
NCT02972151 -
Clinical Research of TCM on Pelvic Inflammatory Disease Sequelae
|
Phase 2 | |
Completed |
NCT01236131 -
The Role of Novel Organisms in Acute Endometritis
|
N/A | |
Active, not recruiting |
NCT03994055 -
Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer
|
N/A | |
Completed |
NCT00871494 -
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
|
Phase 3 | |
Completed |
NCT00783419 -
Rate of Pelvic Inflammatory Disease at St. Michael's Hospital
|
||
Completed |
NCT01799356 -
Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials
|
Phase 4 | |
Recruiting |
NCT05408624 -
Pilot Study Evaluating Outpatient Management of Tubo-ovarian Abscesses
|
||
Completed |
NCT01241110 -
To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment
|
Phase 4 | |
Completed |
NCT00453349 -
A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
|
Phase 3 | |
Recruiting |
NCT04234945 -
Effect of Prophylactic Antibiotics for Hysterosalpingography on Post Procedure Morbidity
|
N/A | |
Recruiting |
NCT06360965 -
Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain
|
N/A | |
Recruiting |
NCT05648747 -
Pelvic Inflammatory Disease in COVID-19 Era
|
||
Completed |
NCT01793584 -
Surgical Success After Laparoscopic vs Abdominal Hysterectomy
|
N/A | |
Completed |
NCT01299259 -
Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease
|
N/A | |
Completed |
NCT03054402 -
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
|
Phase 1 | |
Active, not recruiting |
NCT03828994 -
Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID II
|
N/A |